PHT Provides Mobile Patient Engagement Apps
PHT next week will announce a new suite of clinical research patient engagement apps at the Summit for Clinical Ops Executives conference in Orlando
PHT next week will announce a new suite of clinical research patient engagement apps at the Summit for Clinical Ops Executives conference in Orlando. The PHT Patient Connect Engagement Suite, an integrated set of tools, will now be available as part of the PHT eCOA (electronic clinical outcome assessment) System. The Suite is designed to increase patient engagement and protocol compliance, and help reduce trial participant dropout. Features include: trial-specific FAQs, visit guides, instruction manuals and training; secure patient portal to review data provided and progress dashboard; and a survey tool for collecting feedback, etc.
Read the full release here.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
